» Articles » PMID: 28243992

Chemotherapy-induced Amenorrhea and the Resumption of Menstruation in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer

Overview
Journal Breast Cancer
Specialty Oncology
Date 2017 Mar 1
PMID 28243992
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: For premenopausal women with breast cancer, information on the effects of chemotherapy and the risk of infertility is important. In this study, the effect of chemotherapy on the ovarian function in premenopausal women with hormone receptor-positive breast cancer was investigated, with an age-stratified analysis of the appearance of amenorrhea and the resumption of menstruation after the use of chemotherapy with anthracyclines or taxanes.

Patients And Methods: Premenopausal women diagnosed with operable Stage I-III hormone receptor-positive breast cancer and underwent neoadjuvant or adjuvant chemotherapy with the standard regimen of anthracyclines and/or taxanes were included. The patients were classified into age groups in 5-year increments, and the rates of chemotherapy-induced amenorrhea (CIA), resumption of menstruation, and duration of CIA after chemotherapy were analyzed.

Results: The subjects consisted of 101 patients (median age 45 years). CIA occurred in 97 (96%) patients and 40 patients resumed menstruation. In all patients aged ≤39 years menstruation restarted, whereas in all patients aged ≥50 years, menstruation did not restart. For the patients who resumed menstruation, the younger the patients, the sooner menstruation tended to restart. The resumption of menstruation occurred within 1 year for younger patients aged around 30 years, but for those aged ≥35 years, 60% of cases took around 2-3 years for resumption.

Conclusions: The incidence of CIA, the resumption of menstruation and duration of CIA after chemotherapy depend greatly on the patient's age.

Citing Articles

Contraception Use in Cancer Survivors, Clinical Practice and Patients' Preferences.

Asinaro G, Stigliani S, Chiappe E, Lambertini M, Massarotti C Open Access J Contracept. 2024; 15:135-143.

PMID: 39678079 PMC: 11646390. DOI: 10.2147/OAJC.S431366.


The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

Bornes L, van Winden L, Geurts V, de Bruijn B, Azarang L, Lanfermeijer M Nature. 2024; 637(8044):195-204.

PMID: 39633046 PMC: 11666466. DOI: 10.1038/s41586-024-08276-1.


Characterizing attitudes related to future child-bearing in young women diagnosed with early-stage breast cancer.

Umashankar S, Li M, Blevins K, Kim M, Majure M, Park J Breast Cancer Res Treat. 2024; 204(3):509-520.

PMID: 38194132 PMC: 10959837. DOI: 10.1007/s10549-023-07206-5.


Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.

Kabirian R, Franzoi M, Havas J, Coutant C, Tredan O, Levy C JAMA Netw Open. 2023; 6(11):e2343910.

PMID: 37971739 PMC: 10654794. DOI: 10.1001/jamanetworkopen.2023.43910.


Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis.

Wang Y, Li Y, Liang J, Zhang N, Yang Q Front Oncol. 2022; 12:859974.

PMID: 35463307 PMC: 9022106. DOI: 10.3389/fonc.2022.859974.